MRK logo Merck & Co. +
Merck & Co.
+

Merck & Co. (MRK) Business News

Track Merck & Co. in real time with a live news feed covering Merck & Co. stock news, official press releases, company announcements, and an archive of historical Merck & Co. news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
12:11 PM | Monday | Jul 13, 2026 Zacks Investment Research

FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer

NEW News Thumbnail
8:20 AM | Monday | Jul 13, 2026 Benzinga

Why Merck Stock Is in the Spotlight Today

NEW News Thumbnail
6:46 PM | Friday | Jul 10, 2026 Zacks Investment Research

Merck (MRK) Stock Sinks As Market Gains: Here's Why

News Thumbnail
2:10 PM | Friday | Jul 10, 2026 Business Wire

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

News Thumbnail
9:56 AM | Friday | Jul 10, 2026 Zacks Investment Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

News Thumbnail
9:56 AM | Friday | Jul 10, 2026 Zacks Investment Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

News Thumbnail
10:01 AM | Thursday | Jul 9, 2026 Zacks Investment Research

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

News Thumbnail
8:15 AM | Thursday | Jul 9, 2026 Fool - Investing News

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

News Thumbnail
9:26 AM | Wednesday | Jul 8, 2026 Zacks Investment Research

MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?

News Thumbnail
8:40 AM | Wednesday | Jul 8, 2026 Benzinga

Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday

News Thumbnail
5:30 AM | Tuesday | Jul 7, 2026 Fool - Investing News

The Dividend ETF Quietly Outperforming the S&P 500

News Thumbnail
6:50 PM | Monday | Jul 6, 2026 Zacks Investment Research

Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade

News Thumbnail
11:39 AM | Sunday | Jul 5, 2026 24/7 Wall Street

Why MSTY Shareholders Are Facing Uncapped Losses Despite Weekly Distributions

News Thumbnail
5:17 PM | Thursday | Jul 2, 2026 GuruFocus

Merck & Co Inc (MRK) Shares Surge 3.3% -- What GF Score of 78 Tells Investors

News Thumbnail
2:04 PM | Thursday | Jul 2, 2026 Investors Business Daily

Merck Stock, JPMorgan And Two Others Hit New Highs

News Thumbnail

FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer

Zacks Investment Research

12:11 PM | Monday | Jul 13, 2026

news photo
Loading...

Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.

Read full article redirect
12:11 PM | Monday | Jul 13, 2026

FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer

Zacks Investment Research

Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.

Read full article arrow
NEW News Thumbnail
8:20 AM | Monday | Jul 13, 2026

Why Merck Stock Is in the Spotlight Today

Benzinga

Merck & Co. Inc. (NYSE:MRK) shares are in focus Monday after a wave of analyst activity capped by a new FDA approval for its cancer drug Keytruda.

Read full article arrow
NEW News Thumbnail
6:46 PM | Friday | Jul 10, 2026

Merck (MRK) Stock Sinks As Market Gains: Here's Why

Zacks Investment Research

In the closing of the recent trading day, Merck (MRK) stood at $123.54, denoting a -1.22% move from the preceding trading day.

Read full article arrow
News Thumbnail
2:10 PM | Friday | Jul 10, 2026

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Merck's anti-PD-1 therapies, each in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for the treatment of adult patients with muscle-invasive bla.

Read full article arrow
News Thumbnail
9:56 AM | Friday | Jul 10, 2026

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks Investment Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Read full article arrow
News Thumbnail
9:56 AM | Friday | Jul 10, 2026

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks Investment Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Read full article arrow
News Thumbnail
10:01 AM | Thursday | Jul 9, 2026

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Read full article arrow
News Thumbnail
8:15 AM | Thursday | Jul 9, 2026

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

Fool - Investing News

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

Read full article arrow
News Thumbnail
9:26 AM | Wednesday | Jul 8, 2026

MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?

Zacks Investment Research

MRK trades above its 50- and 200-day SMAs as pipeline progress, acquisitions and Keytruda strength offset patent and vaccine headwinds.

Read full article arrow
News Thumbnail
8:40 AM | Wednesday | Jul 8, 2026

Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday

Benzinga

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Read full article arrow
News Thumbnail
5:30 AM | Tuesday | Jul 7, 2026

The Dividend ETF Quietly Outperforming the S&P 500

Fool - Investing News

This dividend ETF's focus beyond yield continues to pay off for investors.

Read full article arrow
News Thumbnail
6:50 PM | Monday | Jul 6, 2026

Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade

Zacks Investment Research

Merck (MRK) concluded the recent trading session at $126.78, signifying a -2.15% move from its prior day's close.

Read full article arrow
News Thumbnail
11:39 AM | Sunday | Jul 5, 2026

Why MSTY Shareholders Are Facing Uncapped Losses Despite Weekly Distributions

24/7 Wall Street

The YieldMax MSTR Option Income Strategy ETF (NYSEARCA:MSTY) is the single-stock income product retail investors flocked to when MicroStrategy (now Strategy) was climbing alongside Bitcoin.

Read full article arrow
News Thumbnail
5:17 PM | Thursday | Jul 2, 2026

Merck & Co Inc (MRK) Shares Surge 3.3% -- What GF Score of 78 Tells Investors

GuruFocus

On July 02, 2026, Merck and Co Inc (MRK) shares rose 3.3% today, currently priced at $129.56. The stock has experienced significant price appreciation, trading wi

Read full article arrow
News Thumbnail
2:04 PM | Thursday | Jul 2, 2026

Merck Stock, JPMorgan And Two Others Hit New Highs

Investors Business Daily

Merck stock is in a buy zone after hitting a new high. Fellow Dow stock JPMorgan Chase and Amphenol are both trading around entry points.

Read full article arrow
News Thumbnail